Dyne Therapeutics (DYN) Earnings Date, Estimates & Call Transcripts $14.80 +0.02 (+0.16%) As of 09:40 AM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Earnings Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock Dyne Therapeutics Earnings Summary Dyne Therapeutics posted Q1 2025 earnings on May 8, 2025, reporting an EPS of -$1.05, which missed analysts' consensus estimates of -$0.88 by $0.17. With a trailing EPS of -$3.59, Dyne Therapeutics' earnings are expected to decrease next year, from ($3.44) to ($3.62) per share. Upcoming Q2 Earnings DateAug. 11Before Market OpensEstimatedConsensus EPS (May. 8) -$0.88 Actual EPS (May. 8) -$1.05 Missed By -$0.17 Q1 2025 Earnings ResourcesQ1 2025 Earnings Report Quarterly Report (10-Q) Press Release (8-K)DYN Upcoming EarningsDyne Therapeutics' next earnings date is estimated for Monday, August 11, 2025, based on past reporting schedules. Powered by Get Dyne Therapeutics Earnings Alerts Want to stay updated on the latest earnings announcements and upcoming reports? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Dyne Therapeutics and other key companies, straight to your inbox. Enter your email to sign up for newsletter Sign Up Skip Charts & View Estimated and Actual Earnings DataDYN Earnings Estimates and Actuals by QuarterEarnings Estimates and Acutals by Quarter Chart DescriptionThe chart below shows up to four years of a company's earnings history. The dark blue line represents the company's actual earnings per share. The light blue area represents the range of Wall Street analysts' earnings estimates for each quarter. Dyne Therapeutics Analyst EPS EstimatesQuarterNumber of EstimatesLow EstimateHigh EstimateAverage EstimateQ1 20251-$0.90-$0.90-$0.90Q2 20251-$0.91-$0.91-$0.91Q3 20251-$0.91-$0.91-$0.91Q4 20251-$0.91-$0.91-$0.91 Dyne Therapeutics Earnings History by Quarter Custom Range 3 Months 6 Months Year-to-Date 1 Year 2 Years 3 Years 5 Years 10 Years Time Frame * Start Date * End Date Export to Excel DateQuarterConsensus EstimateReported EPSBeat/MissGAAP EPSRevenue EstimateActual RevenueDetails 8/11/2025(Estimated)--------5/8/2025Q1 2025-$0.88-$1.05 -$0.17-$1.05--3/4/2025Q4 2024-$0.92-$0.88+$0.04-$0.88--11/12/2024--$0.71-$0.96 -$0.25-$0.96--8/12/2024--$0.72-$0.70+$0.02-$0.70--5/2/2024Q1 2024-$0.81-$0.81--$0.81--3/5/2024Q4 2023-$0.92-$1.09 -$0.17-$1.09--10/30/2023Q3 2023-$0.83-$0.99 -$0.16-$0.99--8/3/2023Q2 2023-$0.81-$1.08 -$0.27-$1.08-- Dyne Therapeutics Earnings - Frequently Asked Questions When is Dyne Therapeutics's earnings date? Dyne Therapeutics has not confirmed its next earnings publication date, but the company's estimated earnings date is Monday, August 11th, 2025 based off last year's report dates. Learn more on DYN's earnings history. Did Dyne Therapeutics beat their earnings estimates last quarter? In the previous quarter, Dyne Therapeutics (NASDAQ:DYN) missed the analysts' consensus estimate of ($0.88) by $0.17 with a reported earnings per share (EPS) of ($1.05). Learn more on analysts' earnings estimate vs. DYN's actual earnings. How much profit does Dyne Therapeutics generate each year? Dyne Therapeutics (NASDAQ:DYN) has a recorded net income of -$235.94 million. DYN has generated -$3.59 earnings per share over the last four quarters. What is Dyne Therapeutics's EPS forecast for next year? Dyne Therapeutics's earnings are expected to decrease from ($3.44) per share to ($3.62) per share in the next year. More Earnings Resources from MarketBeat Related Companies Grifols Earnings Results TG Therapeutics Earnings Results Nuvalent Earnings Results Legend Biotech Earnings Results Lantheus Earnings Results Axsome Therapeutics Earnings Results ADMA Biologics Earnings Results Vaxcyte Earnings Results Merus Earnings Results Rhythm Pharmaceuticals Earnings Results Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Earnings By Country U.S. Earnings Reports Canadian Earnings Reports U.K. Earnings Reports Latest Articles Broadcom Slides on Solid Earnings, AI Outlook Still StrongFive Below Pops on Strong Earnings, But Rally May StallRed Robin's Comeback: Q1 Earnings Spark Investor HopesOllie’s Q1 Earnings: The Good, the Bad, and What’s NextBroadcom Earnings Preview: AVGO Stock Near Record HighsUlta’s Beautiful Q1 Earnings Report Points to More Gains Aheade.l.f. Beauty Sees Record Surge After Earnings, Rhode Deal This page (NASDAQ:DYN) was last updated on 6/11/2025 by MarketBeat.com Staff From Our PartnersYour Bank Account Is No Longer SafeWhat If Washington Declared That: YOUR Money ISN'T Actually Yours? Sounds insane, but that's exactly what ...Priority Gold | SponsoredMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredTrump wipes out trillions overnight…Is there anybody more powerful than Donald Trump right now? In a single tariff announcement, he wiped out n...Porter & Company | SponsoredElon’s NEXT Big IPO?Cancel your internet TODAY!? Take your latest internet bill and light it on fire… then count the seconds it...Banyan Hill Publishing | SponsoredREVEALED FREE: Our top 3 stocks to own in 2025 and beyondEvery time Weiss Ratings flashed green like this, the average gain on each and every stock has been 303% (incl...Weiss Ratings | SponsoredTrump’s Exec Order #14154 could be a “Millionaire-Maker”Former Presidential Advisor, Jim Rickards, says Trump could “rewire our economy and hand millions of Americans...Paradigm Press | SponsoredJuly 2025 Rule Change to Impact Retirement InvestorsThere's a massive change from a new rule going into effect this July. And it's one the Big Banks are alread...Premier Gold Co | SponsoredHere’s How to Claim Your Stake in Elon’s Private Company, xAIEven though xAI is a private company, tech legend and angel investor Jeff Brown found a way for everyday folks...Brownstone Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Dyne Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Dyne Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
